Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24526
- Registration Number
- NCT02235415
Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 595
- Registration Number
- NCT02233907
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4222
- Registration Number
- NCT02233881
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 716
- Registration Number
- NCT02233920
Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 526
- Registration Number
- NCT02233894
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
Phase 4
Completed
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 705
- Registration Number
- NCT02233023
Efficacy and Safety of Lacidipine in Chronic Stable Angina
Phase 2
Completed
- Conditions
- Angina Pectoris
- Interventions
- Drug: Lacidipine, medium doseDrug: Lacidipine, high doseDrug: Lacidipine, low doseDrug: Placebo
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 283
- Registration Number
- NCT02232607
Tolerability and Safety of Duloxetine BID in Healthy Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02232542
Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 327
- Registration Number
- NCT02232555
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual®
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 834
- Registration Number
- NCT02232594